Trial Profile

A Phase I, First-in-Human randomized, double-masked, placebo-controlled Study of NB1111 in Healthy Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tetrahydrocannabinol valine hemisuccinate (Primary)
Indications Glaucoma; Open-angle glaucoma
Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
Sponsors Skye Bioscience

Most Recent Events

30 Apr 2024 According to a Skye Bioscience media release, data from this trial will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting being held May 5-9, 2024, in Seattle, Washington.
25 Oct 2023 Status changed from active, no longer recruiting to completed, according to a Skye Bioscience media release.
25 Oct 2023 According to a Skye Bioscience media release, data from this trial will be discussed in detail during the Company's virtual Investor Day.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com